-
1.发明申请Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases 审中-公开刺激葡萄糖摄入肌肉细胞和治疗疾病的方法和组合物公开(公告)号：US20070054851A1
公开(公告)日：2007-03-08
申请号：US11442244
申请日：2006-05-30
申请人： Junyu Lin , Srinivas Kothakota , Ge Wu , Stephen Doberstein , Thomas Brennan , Lorianne Masuoka , Minmin Qin , Shannon Marshall , Yan Wang , Diane Hollenbaugh , Lewis Williams
发明人： Junyu Lin , Srinivas Kothakota , Ge Wu , Stephen Doberstein , Thomas Brennan , Lorianne Masuoka , Minmin Qin , Shannon Marshall , Yan Wang , Diane Hollenbaugh , Lewis Williams
IPC分类号： A61K38/18
CPC分类号： A61K38/1883 , A61K31/155 , A61K31/18 , A61K31/195 , A61K31/197 , A61K38/1808 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/60 , A61K2300/00
摘要： The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.
摘要翻译： 本发明涉及ErbB配体（包括β细胞素）的治疗用途。 治疗用途包括单独使用ErbB配体家族化合物或与其它药物联合用于降低血糖水平，治疗I型和II型糖尿病，肥胖症，肌肉消瘦疾病和心脏毒性的方法。
-
2.发明申请METHODS OF AND COMPOSITIONS FOR STIMULATION OF GLUCOSE UPTAKE INTO MUSCLE CELLS AND TREATMENT OF DISEASES 审中-公开用于刺激葡萄糖摄入到肌肉细胞和治疗疾病的方法和组合物公开(公告)号：US20110319324A1
公开(公告)日：2011-12-29
申请号：US12955779
申请日：2010-11-29
申请人： Junyu Lin , Srinivas Kothakota , Ge Wu , Stephen Doberstein , Thomas Brennan , Lorianne Masuoka , Minmin Qin , Shannon Marshall , Yan Wang , Diane Hollenbaugh , Lewis T. Williams
发明人： Junyu Lin , Srinivas Kothakota , Ge Wu , Stephen Doberstein , Thomas Brennan , Lorianne Masuoka , Minmin Qin , Shannon Marshall , Yan Wang , Diane Hollenbaugh , Lewis T. Williams
CPC分类号： A61K38/28 , A61K31/155 , A61K38/1808 , A61K38/26 , A61K38/00
摘要： The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.
摘要翻译： 本发明涉及ErbB配体（包括β细胞素）的治疗用途。 治疗用途包括单独使用ErbB配体家族化合物或与其它药物联合用于降低血糖水平，治疗I型和II型糖尿病，肥胖症，肌肉消瘦疾病和心脏毒性的方法。
-
3.发明申请Compositions and methods of use of Semaphorin 3F and antagonists thereof in the stimulation of neuromuscular regeneration and treatment of muscular diseases 审中-公开信号素3F及其拮抗剂在刺激神经肌肉再生和治疗肌肉疾病中的组成和使用方法公开(公告)号：US20070054852A1
公开(公告)日：2007-03-08
申请号：US11442294
申请日：2006-05-30
申请人： Junyu Lin , Ge Wu , Srinivas Kothakota , Lorianne Masuoka
发明人： Junyu Lin , Ge Wu , Srinivas Kothakota , Lorianne Masuoka
CPC分类号： C12Q1/6883 , A61K38/1703 , C12Q2600/158 , G01N2333/4704 , G01N2500/04 , Y02A50/465
摘要： The present invention relates to therapeutic uses of Semaphorin 3F or related proteins. The therapeutic uses include methods of using Semaphorin 3F compounds alone, or in conjunction with other agents, for the stimulation of neuromuscular regeneration, and the treatment of diseases or conditions characterized by muscle denervation and muscle atrophy.
摘要翻译： 本发明涉及信号素3F或相关蛋白的治疗用途。 治疗用途包括单独使用信号素3F化合物或与其他药物联合用于刺激神经肌肉再生以及以肌肉去神经支配和肌肉萎缩为特征的疾病或病症的治疗的方法。
-
4.发明申请Compositions and Methods for Treating Diseases, Disorders, or Conditions Characterized by Myelin Degeneration, Myelin Deficiency or Loss 审中-公开治疗由髓磷脂退化，髓鞘缺乏或损失表征的疾病，疾病或病症的组合物和方法公开(公告)号：US20100210829A1
公开(公告)日：2010-08-19
申请号：US12530447
申请日：2008-03-07
IPC分类号： C07H21/04
CPC分类号： C07K14/4713 , C07K14/47
摘要： Provided herein are novel polypeptides, polynucleotides and compositions containing such, and to methods useful in treating diseases, disorders, or conditions of the central nervous system (CNS) associated with demyelination. The novel polypeptides, polynucleotides stimulate oligodendrocyte precursor cell (OPC), and are capable of promoting myelination or remyelination in a subject.
摘要翻译： 本文提供了新型多肽，多核苷酸和含有此类物质的组合物，以及可用于治疗与脱髓鞘相关的中枢神经系统（CNS）的疾病，病症或病症的方法。 新型多肽，多核苷酸刺激少突胶质细胞前体细胞（OPC），并且能够促进受试者的髓鞘形成或髓鞘再生。
-
5.发明申请Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention 审中-公开成纤维细胞生长因子受体1,2,3和4作为治疗干预的目标公开(公告)号：US20070248605A1
公开(公告)日：2007-10-25
申请号：US10583146
申请日：2004-12-17
申请人： Kevin Hestir , Kristen Pierce , Lewis Williams , Lorianne Masuoka , Justin Wong , Keting Chu
发明人： Kevin Hestir , Kristen Pierce , Lewis Williams , Lorianne Masuoka , Justin Wong , Keting Chu
IPC分类号： A61K39/395 , C07K16/22 , G01N33/53
CPC分类号： C07K16/2863 , C07K14/71 , G01N33/574 , G01N33/74 , G01N2333/50 , G01N2800/04 , G01N2800/065 , G01N2800/085 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/324
摘要： A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.
摘要翻译： 提供了一种组合物，其包含多肽和调节剂或包含该多肽的调节剂和调节剂，其中调节剂特异性干扰多肽的活性，并且该多肽是FGFR3或FGFR4，包括所有多晶型及其变体 。 调节剂可以是抗体或其活性片段，小分子药物，RNAi分子，反义分子或核酶。 还提供了治疗受试者的肿瘤的方法，其中向受试者施用FGFR3或FGFR4的拮抗剂。
-
6.发明申请METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES 失效使用拮抗剂抗CD40抗体治疗B细胞恶性肿瘤的方法公开(公告)号：US20080075727A1
公开(公告)日：2008-03-27
申请号：US11849107
申请日：2007-08-31
申请人： Keting Chu , Lorianne Masuoka
发明人： Keting Chu , Lorianne Masuoka
IPC分类号： A61K39/395 , A61P43/00 , C07K16/18 , C12N5/06
CPC分类号： C07K16/2878 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C12N2799/026
摘要： Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
摘要翻译： 提供了B细胞恶性肿瘤治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 当抗体结合正常人B细胞上的CD40抗原时，拮抗性抗-CD40抗体或其抗原结合片段没有明显的激动剂活性，当抗体结合恶性人B细胞上的CD40抗原时，拮抗剂抗CD40抗体或其抗原结合片段， 当抗体结合正常人B细胞上的CD40抗原时，可以显示拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制恶性人B细胞的增殖和/或分化。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.036 秒)
